Jiawei Gui

ORCID: 0000-0003-3016-0462
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Ferroptosis and cancer prognosis
  • Genetic Associations and Epidemiology
  • Viral-associated cancers and disorders
  • Atherosclerosis and Cardiovascular Diseases
  • Gastrointestinal motility and disorders
  • Cell Adhesion Molecules Research
  • RNA modifications and cancer
  • Sirtuins and Resveratrol in Medicine
  • Cancer Immunotherapy and Biomarkers
  • Diet and metabolism studies
  • Gut microbiota and health
  • Cancer-related molecular mechanisms research
  • Foot and Ankle Surgery
  • Inflammatory Biomarkers in Disease Prognosis
  • Curcumin's Biomedical Applications
  • Biochemical effects in animals
  • PI3K/AKT/mTOR signaling in cancer
  • Nuclear Receptors and Signaling
  • MicroRNA in disease regulation
  • RNA and protein synthesis mechanisms

Nanchang University
2024-2025

Hubei University of Medicine
2024

Xiang Yang No.1 People's Hospital
2024

First Affiliated Hospital of Jiangxi Medical College
2024

Jiangxi Provincial Academy of Medical Sciences
2024

Harbin Medical University
2023

Second Affiliated Hospital of Harbin Medical University
2023

Dartmouth College
2017

Transporter 2, ATP binding cassette (ABC) subfamily B member (TAP2), encodes a protein within the ABC transporter superfamily. TAP2 plays role in progression of cancers, such as cervical, breast, and lung cancers. However, relationship between cancer prognosis, immune cell infiltration, tumor microenvironment, immunotherapy remains unexplored. Therefore, this study aims to investigate effect expression on its predicting prognosis efficacy. Bioinformatics analyses Gene Set Enrichment...

10.1186/s40001-025-02360-6 article EN cc-by-nc-nd European journal of medical research 2025-03-13

The integrin subunit α3 (ITGA3) is a member of the alpha chain protein family, which could promote progression, metastasis, and invasion in some cancers. Still, its function tumor microenvironment (TME), cancer prognosis, immunotherapy remains unclear. A multifaceted analysis ITGA3 pan-cancer utilizing various databases online web tools revealed was aberrantly expressed tissues upregulated most cancers, may be related to genomic alterations methylation modification. In addition,...

10.1016/j.heliyon.2024.e24236 article EN cc-by-nc-nd Heliyon 2024-01-01

While observational studies link immune cells with post-stroke functional outcome, the underlying mechanisms are not well understood. Immune cell surface antigens actively involved in biological behavior of cells, investigating could deepen our comprehension their role and processes stroke recovery. Therefore, we aimed to investigate immunological basis outcome by exploring causal relationship between after ischemic a Mendelian randomization study. Genetic variants related were selected for...

10.3389/fimmu.2024.1353034 article EN cc-by Frontiers in Immunology 2024-03-18

Laryngeal cancer was one of the most common malignancies head in those years. It has become causes death due to its high recurrence rate and metastasis rate. well known that platelets, especially activated promote proliferation, division, invasion tumor cells. Activated platelets progression metastasis. However, prognostic value platelet aggregation function laryngeal remains poorly understood. The purpose this study investigate predictive significance cancer.Between January 2015 December...

10.2147/ijgm.s428122 article EN cc-by-nc International Journal of General Medicine 2023-11-01

To investigate the protective effect of resveratrol on intestinal barrier in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced Parkinson's disease (PD) mouse models and its mechanism for regulating TLR4/MyD88/NF-κB signaling to protect dopaminergic neurons.

10.12122/j.issn.1673-4254.2024.02.09 article EN PubMed 2024-02-20

To investigate the clinical efficacy of simultaneous arthroscopic repair anterior talofibular ligament (ATFL) and calcaneofibular (CFL) for treating chronic lateral ankle instability (CLAI) in conjunction with subtalar (STI).

10.3760/cma.j.cn112139-20240229-00092 article EN PubMed 2024-06-01

Abstract The mTORC1 inhibitor everolimus (afinitor) is approved for the treatment of patients with advanced/metastatic ER+/HER2- breast cancer in combination steroidal aromatase exemestane following progression on a non-steroidal inhibitor. BOLERO-2 and TAMRAD studies demonstrated that combined everolimus/anti-estrogen therapy provided longer PFS compared to anti-estrogen alone. However, it has not been clarified whether continued an backbone beneficial setting inhibition. Upon activation by...

10.1158/1538-7445.sabcs16-p3-04-11 article EN Cancer Research 2017-02-15
Coming Soon ...